Skeletal Myoblast Cells. 2 Skeletal myoblasts Derived from satellite cells in skeletal muscle With appropriate stimulus, satellite cells differentiate.

Slides:



Advertisements
Similar presentations
Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
Advertisements

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Myocardial Repair by Percutaneous Cell Transplantation of Autologous Skeletal Myoblast as a Stand Alone Procedure in Post Myocardial Infarction Chronic.
4th International Symposium on Stem Cell Therapy Madrid, April 26-27, 2007 Stem Cell Thertapy for STEMI. Is is Time for a Large Scale Clinical Trial ?
M. Valgimigli University of Ferrara Italy Autologous bone marrow stem cell mobilization Induced by G-CSF after MI Autologous bone marrow stem cell mobilization.
Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
1 BIOHEART INC. February 2012 OTC: BHRT.OB The Next Generation of Regeneration.
CHARM Program: 3 Component trials comparing candesartan with placebo.
Copyleft Clinical Trial Results. You Must Redistribute Slides SEISMIC Trial The Safetyand Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell)
Skeletal myoblasts after myocardial infarction and inducibility of ventricular arrhythmias Patricia Lemarchand.
Stem Cell Implants to Repair Damaged Hearts Rationale Two clinical trials – Cardiac-derived stem cells Cedars Sinai Medical Center, Dr. Eduardo Marban.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Stem cell therapy in cardiac practice
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
Impact of ISDN-hydralazine on mortality and morbidity of African-American patients with Heart Failure A-Heft Trial Presented at American Heart Association.
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.
Cell Therapy in CV Disease: Future Directions. 2 Anversa P, Nadal-Ginard B et al. Nature. 2002;415: Cardiac renewal: Is the goal in sight? “Remaining.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Jasna Marinović, M.D., Ph.D. Associate Professor Department of Physiology.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
An ICD for every CRT patient ?
Diagnosis of acute MI Pharmacologic therapy* Immediate angiography PTCAPTCA Other Rx *Antithrombin agents, antiplatelet agents, and fibrinolytic agents.
STICH CABG Objective To determine whether surgery plus medical management or medical management alone improve outcomes in CABG patients Study Design 1212.
Panel PresenationFDA Clinical Review1 CDRH Panel Meeting June 22, 2005 Ileana L. Piña, M.D. Professor of Medicine Case Western Reserve University Director.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
The ixCELL-DCM Trial: Transendocardial Injection of ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy Timothy D. Henry, MD, FACC on behalf.
The ixCELL-DCM Trial: Transendocardial Injection of ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy Timothy D. Henry, MD, FACC on behalf.
Pax 7 is Necessary For the Myogenic Specification of CD45+ Stem Cells Reviewed by Heather Hall Research by Patrick Seale, Jeff Ishibashi, Anthony Scime,
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
Left Ventricular Pacing in the Early Post MI Period: Impact on LV Remodeling Eugene S.Chung, MD Director, Heart Failure Program, Director of Outcomes,
The TIME Randomized Trial:
The NHLBI TIME Trial: Role of Microvascular Obstruction in 2-Year Clinical and MRI Follow-up Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis.
Extending the Boundaries of TAVR: Future Directions
Jeff Macemon MBChB, PDMSM Advanced Trainee, CTS
Revascularization in Patients With Left Ventricular Dysfunction:
Phase I Clinical Trial of Autologous Stem Cell–Sheet Transplantation Therapy for Treating Cardiomyopathy by Shigeru Miyagawa, Keitaro Domae, Yasushi Yoshikawa,
Cardiovacular Research Technologies
BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.
Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: A meta-analysis  Peter Donndorf, MD, Guenther Kundt, PhD,
Cardiac Cell Repair Therapy: A Clinical Perspective
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.
Trial profile John A Dormandy et al. Lancet 2005;366:
MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo.
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.
(p = 0.32 for noninferiority)
Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo.
Myoblast Transplantation for Cardiac Repair: A Clinical Perspective
EMERGING ROLE OF STEM CELLS In CARDIOVASCULAR THERAPY
POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.
CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.
The FAIR-HF Trial Reference
SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.
Association of electrostimulation with cell transplantation in ischemic heart disease  Abdel Shafy, MD, Thomas Lavergne, MD, Christian Latremouille, MD,
Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model  Hiroki Hata, MD, Goro Matsumiya, MD, PhD,
Eduardo Marbán, MD, PhD  Mayo Clinic Proceedings 
Zhi Cui, MSc, Ren-Ke Li, MD, PhD 
Absolute mortality difference Change in LVEF from baseline
Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
PHOENIX I: PASI 75 Response After 12 Weeks
(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.
Presentation transcript:

Skeletal Myoblast Cells

2 Skeletal myoblasts Derived from satellite cells in skeletal muscle With appropriate stimulus, satellite cells differentiate into muscle fibers Highly resistant to ischemia Do not contract spontaneously Do not differentiate into cardiomyocytes

3 Human skeletal myoblasts after 3-wk in vitro culture period (magnification ×40) Skeletal myoblasts 2-3 cm biopsy sample of thigh vastus lateralis (12-18 g) explanted under local anesthesia Courtesy of Arshed A. Quyyumi, MD.

4 Before surgery After surgery Menasché P et al. Lancet. 2001;357: Skeletal myoblast transplantation in post-MI HF patients

5 Autologous skeletal myoblast injection for ischemic cardiomyopathy trial (MAGIC) Patients: –Moderate to severe LVSD referred for CABG Cells: –Muscle Bx from thigh –Skeletal muscle myoblasts cultured Delivery: –Direct injection into scar at surgery Results: –Stopped early by DSMB due to low enrollment rate –Adverse event rate similar (25% cells vs 20% controls) –ICD Therapy in 15% –No improvement in LVEF by TTE (primary outcome)* –LVEF improved by SPECT –Highly significant dose-dependent LV size decrease Cleland JGF et al. Eur J Heart Failure 2007;9: Placebo Low-Dose Myoblasts High-Dose MyoblastP value Patients enrolled Patients injected Change in LVEF (echo)* +4.4%+3.4%+5.2% NS Change in LVEF (nuc) 02%3% <0.04 Change in LVEDD (mL) +9 (-21 to 28) -9 (-33 to 25) -23 (-42 to 0) 0.006